The Pharmaceutical Benefits Scheme (PBS) consumes around 14 percent of total government health care expenditures and has grown substantially in both range of drugs covered, and expenditure since it was first introduced in 1950. Proponents of drug price regulation argue that drug makers raise prices to benefit the value of their stock and invest little of their profits in the development and research of new drugs. Opponents of regulation argue that consumers rely on drug companies to develop new drugs and limiting prices will prevent new lifesaving drugs from being developed.
91% Taip |
9% Nr |
87% Taip |
6% Nr |
2% Yes, and we should socialize medicine and healthcare |
1% No, limiting drug prices would also limit the investment in research and development into new life-saving drugs |
2% Yes, and the government should regulate the price of all prescription drugs |
1% No, but shorten the lifespan of drug patents |
0% No, and the government should never regulate prices of private businesses |
Pažiūrėkite, kaip laikui bėgant pasikeitė 243k Australija rinkėjų parama kiekvienai pozicijai dėl “Drug Price Regulation” .
Įkeliami duomenys...
Įkeliama diagrama...
Pažiūrėkite, kaip laikui bėgant pasikeitė “Drug Price Regulation” svarba 243k Australija rinkėjų.
Įkeliami duomenys...
Įkeliama diagrama...
